What does this research mean for the field?

Continuous prostacyclin therapy significantly decreases elevated plasma P-selectin levels and increases decreased thrombomodulin levels in patients with pulmonary arterial hypertension. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

November 28, 2000CirculationOpen Access

Increased Plasma P-Selectin and Decreased Thrombomodulin in Pulmonary Arterial Hypertension Were Improved by Continuous Prostacyclin Therapy

Q: What are the key findings of this study?

Continuous prostacyclin therapy significantly increased thrombomodulin levels and decreased P-selectin levels in patients with primary and secondary pulmonary arterial hypertension (P<0.05).

Q: What is the clinical evidence from this study?

Study design: Observational. Population: Pulmonary hypertension (n=105). Intervention: Continuous prostacyclin therapy vs. Baseline (pre-therapy). Primary outcome: Plasma levels of soluble P-selectin and thrombomodulin (p=<0.05).

View Full Paper

Ask AI

Bookmark

Key result

Continuous prostacyclin is linked to higher thrombomodulin and lower P-selectin levels in PAH.

P<0.05
n=105

Why the study?

Thrombosis in situ related to endothelial cell injury may contribute to pulmonary hypertension, but the role of P-selectin and thrombomodulin in this process was unclear.

Does continuous prostacyclin therapy improve plasma levels of P-selectin and thrombomodulin in patients with pulmonary arterial hypertension?

Study Design

Type

Observational (n=105)

Structured PICO

Does continuous prostacyclin therapy improve plasma levels of P-selectin and thrombomodulin in patients with pulmonary arterial hypertension?

Population

105 participants including 32 with primary pulmonary hypertension, 25 with secondary pulmonary arterial hypertension, 31 with pulmonary venous hypertension, and 17 healthy controls.

Intervention

Continuous infusion of prostacyclin (evaluated in a subset of 15 patients with PPH and 3 with sPAH).

Comparator

Healthy controls and PVH patients for baseline comparisons; pre-treatment baseline for the prostacyclin therapy subset.

Outcome

Plasma levels of soluble P-selectin and thrombomodulin (TM)surrogate

Main Result

p-value: p=<0.05

Continuous prostacyclin therapy improves biomarkers of endothelial injury and altered hemostasis (P-selectin and thrombomodulin) in patients with pulmonary arterial hypertension.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Coagulation marker shifts after prostacyclin in PH are hypothesis-generating; leaves open clinical relevance and need for larger outcome trials.

Cite This Study

Sakamaki et al. (2000) conducted an observational in Pulmonary hypertension (n=105). Continuous prostacyclin therapy vs. Baseline (pre-therapy) was evaluated on Plasma levels of soluble P-selectin and thrombomodulin (p=<0.05). Continuous prostacyclin therapy significantly increased thrombomodulin levels and decreased P-selectin levels in patients with primary and secondary pulmonary arterial hypertension (P<0.05).

synapsesocial.com/papers/6a6ea0face524a4339c30868 https://doi.org/10.1161/01.cir.102.22.2720

View Full Paper

Ask AI

Bookmark

Implication

Coagulation marker shifts after prostacyclin in PH are hypothesis-generating; leaves open clinical relevance and need for larger outcome trials.

Increased Plasma P-Selectin and Decreased Thrombomodulin in Pulmonary Arterial Hypertension Were Improved by Continuous Prostacyclin Therapy

Study Design

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Increased Plasma P-Selectin and Decreased Thrombomodulin in Pulmonary Arterial Hypertension Were Improved by Continuous Prostacyclin Therapy

Study Design

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Also Consider

Also Consider